Pharmesis International (SGX:BFK) Other Current Liabilities: S$2.02 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
34 GF Score
Price S$0.13
GF Value S$0.16
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Pharmesis International Other Current Liabilities?

Pharmesis International SGX:BFK 34 Other Current Liabilities is S$2.02 Mil as of Jun. 2026. GuruFocus rates SGX:BFK with a GF Score™ of 34/100 and a GF Value™ of S$0.16 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Pharmesis International's other current liabilities for the quarter that ended in Jun. 2026 was S$2.02 Mil.

Pharmesis International's quarterly other current liabilities declined from Jun. 2025 (S$1.52 Mil) to Dec. 2025 (S$0.58 Mil) but then increased from Dec. 2025 (S$0.58 Mil) to Jun. 2026 (S$2.02 Mil).

Pharmesis International's annual other current liabilities increased from Dec. 2023 (S$0.51 Mil) to Dec. 2024 (S$0.53 Mil) and increased from Dec. 2024 (S$0.53 Mil) to Dec. 2025 (S$0.58 Mil).

Pharmesis International Other Current Liabilities Related Terms

Pharmesis International Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pharmesis International's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Other Current Liabilities Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 1.81 0.51 0.53 0.58

Pharmesis International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.53 1.52 0.58 2.02
SGX:BFK
34GF Score
Pharmesis International Ltd SGX:BFK
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of S$2.02 Mil mean?
Pharmesis International (SGX:BFK) has a Other Current Liabilities of S$2.02 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharmesis International.
Is Pharmesis International's Other Current Liabilities too high?
Pharmesis International's current Other Current Liabilities is S$2.02 Mil. Overall, Pharmesis International has a GF Score™ of 34/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Other Current Liabilities compare to ZTS and UTHR?
Pharmesis International's Other Current Liabilities of S$2.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharmesis International. Pharmesis International's current Other Current Liabilities is S$2.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Undervalued. The stock's GF Value™ is S$0.16, compared to a current price of S$0.13 — trading 21.9% below its estimated fair value. The current Other Current Liabilities is S$2.02 Mil. Pharmesis International's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Other Current Liabilities is S$2.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be undervalued. The current stock price of S$0.13 is trading 21.9% below its estimated GF Value™ of S$0.16. GuruFocus considers Pharmesis International to be Modestly Undervalued.

Key valuation signals for SGX:BFK:

  • Other Current Liabilities: S$2.02 Mil
  • GF Value™: S$0.16 vs. price of S$0.13 (21.9% below fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
34GF Score

Get the complete analysis for SGX:BFK

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.13
Price
S$0.16
GF Value